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Tetherin is a broadly active antiviral effector that works by tethering nascent enveloped virions to a host cell membrane,
thus preventing their release. In this study, we demonstrate that herpes simplex virus 1 (HSV-1) is targeted by tetherin. We
identify the viral envelope glycoprotein M (gM) as having moderate anti-tetherin activity. We show that gM but not gB or
gD efficiently removes tetherin from the plasma membrane and can functionally substitute for the human immunodefi-
ciency virus type 1 (HIV-1) Vpu protein, the prototypic viral tetherin antagonist, in rescuing HIV-1 release from tetherin-
expressing cells. Our data emphasize that tetherin is a broadly active antiviral effector and contribute to the emerging hy-
pothesis that viruses must suppress or evade an array of host cell countermeasures in order to establish a productive
infection.
Mammalian cells encode restriction factors that provide thehost with protection against virus replication. In order to
establish a productive infection, a virus must evade or suppress a
repertoire of restriction factors directed against it by the host.
Restriction has been studied most extensively in the context of
retrovirus infections, where numerous factors and the corre-
sponding viral antagonists have beenwell characterized (1).While
some restriction factors, such as TRIM5, appear to be specific for
particular classes of virus, in this case retroviruses, others, such as
tetherin, are broadly active against unrelated viruses. Tetherin
(also known as BST-2, CD317, or HM1.24) was identified as the
cellular factor responsible for suppression of Vpu-negative hu-
man immunodeficiency virus type 1 (HIV-1) (2, 3), but subse-
quent work has shown that it is effective against a variety of envel-
oped viruses (2, 4–8) that use distinct mechanisms to antagonize
its restrictive effects (9–12). Tetherin is a type 2 integral mem-
brane protein with a C-terminal GPI anchor. The antiviral activity
of tetherin stems from this unusual double membrane-linked to-
pology that allows the formation of a protein tether between the
host membrane and the budding viral envelope, preventing re-
lease of nascent virions (13).
Herpesviruses, a large family of enveloped DNA viruses, are
ancient pathogens thought to have coevolved with their hosts
for many generations (14). As such, they might be expected to
possess countermeasures to a variety of restriction factors and
thus to provide a good experimental model system for studies
of this aspect of the virus host interaction. To date, two mem-
bers of this virus family, Kaposi’s sarcoma-associated herpes-
virus (KSHV) and human cytomegalovirus (HCMV), have
been shown to interact with tetherin (15–17). Surprisingly, the
mode of interaction differs for these two viruses, with tetherin
acting as a restriction factor for KSHV but as an entry cofactor
for HCMV. In this study, we investigated the effect of tetherin
on another human herpesvirus, herpes simplex virus 1 (HSV-
1). We show that tetherin restricts the HSV-1 replication cycle
by suppressing virus release, and we identify the viral envelope
glycoprotein M (gM) as a countermeasure contributing to an-
tagonism of tetherin restriction.
MATERIALS AND METHODS
Cell lines, plasmids, and viruses. HT1080 cells expressing internally
hemagglutinin (HA)-tagged human tetherin (at amino acid 154) or
empty vector (LHCX) are nonclonal drug-selected populations and have
been described (16), as has the tetherin expression vector pCR3.1/hu-
Tetherin-HA (18). The HSV-1 gM (UL10) gene was PCR amplified from
HSV-1 17-infected-cell DNA and inserted into pCDNA3. The HSV-1
gB (UL27) and gD (US6) plasmids (pSR175 and pSC390) were gifts
from Roselyn Eisenberg and Gary Cohen (University of Pennsylvania)
(19, 20). Plasmids expressing Vpu, in pCDNA3 (for HIV-1 release assay)
or pIRESeGFP (for flow cytometry), were described previously (21).
Wild-type (WT) HSV-1 SC16 and HSV-1 KOS K26GFP, encoding a
VP26-green fluorescent protein (GFP) fusion protein (22) were gifts from
Gillian Elliott (Imperial College London). HSV-1 with a deletion of UL10
(gM) and its revertant (RgM) were gifts from Helena Browne (Univer-
sity of Cambridge), and their construction has been described (23).
HSV-1 replication assay. HT1080 cells (3  105 cells/well, 6-well
plates) were chilled to 4°C and then incubated with HSV-1 for 1 h. Plates
were then refed and transferred to 37°C for a further hour. The medium
was then removed and replacedwith acid-citrate buffer (500l, pH3.0) to
inactivate extracellular virus, followed by the addition of fresh medium.
Infected-cell culture supernatants were recovered at various times postin-
fection and centrifuged to remove cellular debris, and virus titers deter-
mined by plaque assay on Vero cells. For cell-associated virus titers, cells
were lysed by 3 freeze-thaw cycles into an equal volume of medium,
cleared by centrifugation, and titrated as described above. The HSV-1
proteins ICP4 and VP5 were detected in infected-cell lysates by immuno-
blotting using specific antibodies (Santa Cruz). As a loading control we
detected -actin (Abcam) on stripped blots.
RNA interference.Weused lentiviral vectors encoding tetherin-specific
hairpins (shRNA1, 5=-GGAGUUCUGGUGUUCCUGAUUAUUUCGAUG
AUCAGGAGCACCAGAAUUCC-3=; shRNA2, 5=-GUGGGAAUCGUGGA
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UAAGAAGUAUUCGUACUUCUUGUCCGCGAUUCUCAC-3=; under-
lining indicates tetherin-targeted sequence) or a GFP hairpin (24) as a
control.Depletionwas examinedby immunoblotting or by quantitative PCR
on cDNA (see below). Cells were infected with HSV-1 96 h post-shRNA
transduction as described above.
Quantification of tetherin and HSV-1 by TaqMan PCR. Encapsi-
dated HSV-1 genomes were quantified by extracting total DNA from
DNase I-treated supernatants or infected-cell lysates as described previ-
ously (16). DNAwas subjected to quantitative TaqMan PCR (Q-PCR) for
HSV-1 UL27 as described previously (25). Absolute copy number was
determined by reference to a standard curve, plotted using serial dilutions
of a cloned UL27 amplicon with a detection limit of 10 UL27 copies/15l
of supernatant. Copy numbers were normalized to extracted DNA carrier
concentration (supernatants) or to quantities of extracted DNA (cells).
Total mRNA was extracted from transduced HeLa cells or from HT1080
cells expressing HA-tagged tetherin and infected with HSV-1 SC16 or not
infected, and cDNA was synthesized for use as the template in TaqMan
Q-PCRs for tetherin and GAPDH. Tetherin primers were as follows: for-
ward, 5=-ACCTGCAACCACACTGTGATG-3=; reverse, 5=-CAAGCTCCT
CCACTTTCTTTTGTC-3=; tetherin probe, 5=-FAM-CCCTAATGGCTTCC
CTGGATGCAGA-TAMRA-3=. Absolute copynumberwas determinedwith
reference to a standard curve derived using a tetherin-encoding plasmid. Q-
PCR for GAPDHwas performed as described previously (16).
Flow cytometry. For tetherin cell surface staining, HEK293T cells in
6-well plates were transfected (Fugene-6; Roche) with pCR3.1/hu-Teth-
erin-HA and 250 ng, 500 ng, or 1,000 ng of plasmids expressing gM, gD, or
gB (21). A pIRES2eGFP plasmid coding for Vpu was used as a control. At
48 h posttransfection, cell surface tetherin expression was examined on
unfixed live cells with an anti-HA monoclonal antibody (Covance) and
analyzed by flow cytometry. The mean fluorescence intensity of tetherin
staining was measured as described previously (7). HSV-1 glycoproteins
were detected by immunoblotting with a rabbit anti-gM (23), a rabbit
anti-gD R8 (26), or a goat anti-gB (Santa Cruz) antibody after membrane
stripping. As a loading control, we detected-actin, GAPDH (Abcam), or
transferrin receptor (Invitrogen).
HIV-1 release assay.Toprepare vesicular stomatitis virusG glycopro-
tein (VSV-G)-pseudotyped HIV-1 particles, 106 HEK293T cells were
cotransfected with the Gag-Pol expression vector p8.91 (300 ng), pMDG
encodingVSV-G (300 ng), andHIV-1 vector encoding YFP (450 ng) (27).
Tetherin construct (100 ng) was cotransfected along with either 250 ng,
500 ng, or 1,000 ng of HSV-1 gM, gB, or gD or HIV-1 Vpu plasmid. DNA
dose was equalized with the empty vector pcDNA3 (Invitrogen). After 48
h, cell-associated p55 Gag and p24 capsid and p24 capsid in the superna-
tant were detected by immunoblotting as described previously (27). The
intensity of p55 bands in cell lysates and p24 bands in virions was analyzed
with Image Studio 3.1.4 software (LI-COR), and ratios of p55 to p24 were
calculated with signal intensity percentages relative to values obtained in
the absence of tetherin.
Microscopy. For electron microscopy, 1 105 HT1080 cells express-
ing HA-tagged tetherin or control cells seeded on coverslips were infected
with 2 105 (experiment 1) or 1 105 (experiment 2) PFU (determined
onVero cells) ofHSV-1K26GFP (HT1080 cells are an order ofmagnitude
less permissive than Vero cells to HSV-1, and therefore multiplicities for
these experiments can be estimated to be 0.2 and 0.1 PFU/cell, respec-
tively). After 16 h, the cells were fixed for 45min in 2% paraformaldehyde
(PFA)–2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4),
postfixed for 1 h on ice in 1%OsO4–1.5%K3[Fe(CN)6], treatedwith 1.5%
tannic acid (TAABLaboratories), dehydrated, and embedded in Epon 812
(TAAB). Ultrathin sections (70 nm) were cut en face on a Leica EM UC7
ultramicrotome, placed on Formvar-coated slot grids, and stained with
lead citrate. Sections were examined with a Tecnai G2 Spirit transmission
EM (FEI), and digital images were recorded with a Morada 11 MegaPixel
transmission electronmicroscopy (TEM) camera (Olympus Soft Imaging
Solutions) and ANALYSIS software. Images were adjusted for brightness
and contrast, and figures were assembled with Photoshop CS. To deter-
mine the numbers of cell surface HSV-1 particles, at least 50 consecutive/
adjacent cell profiles in the section were inspected for each sample. Cir-
cular profiles of HSV-1 particles, measuring between 80 and 180 nm in
diameter and with the morphologies indicated in Fig. 3, were counted.
For confocal microscopy, HEK293T cells were plated on poly-L-
lysine-coated coverslips in 24-well plates and transfected (Fugene-6;
Roche)with plasmids encoding gM, gB, or gD and/orHA-tagged tetherin.
Between 20 and 48 h later, cells were fixed (4%PFA), permeabilized (0.1%
Triton X-100), and stained using anti-HA (Covance), rabbit anti-gM,
rabbit anti-gD R8, goat anti-gB, or sheep anti-TGN46 (Serotec) antibod-
ies and secondary antibodies linked to Alexa-488, -594, or -633 (Molecu-
lar Probes) or rhodamine (Pierce). Cells were observed using a Leica TCS
SPE, DM2500, confocal microscope (Leica Microsystems). Images were
adjusted for brightness and contrast withAdobe Photoshop software 10.0.
RESULTS
Tetherin restricts HSV-1 particle release. To seek evidence for
restriction of HSV-1, we expressed HA-tagged human tetherin in
HT1080 cells. These cells were chosen because they naturally ex-
press very low levels of tetherin and are highly permissive for
HSV-1 (28). As a control, we used HT1080 cells transduced with
empty vector. We hypothesized that tetherin overexpression
might saturate any anti-tetherin activities mediated by the virus
and reveal tetherin sensitivity. We infected both HT1080 cell lines
with HSV-1 SC16 at a low multiplicity (0.01 PFU/cell), aiming to
study the effect of tetherin in a multicycle infection by measuring
the titer of virus released at various times by plaque assay on Vero
cells. Tetherin expression consistently reduced the levels of infec-
tious virus released, leading to a 14-fold reduction at 48 h postin-
fection (hpi), compared to controls (Fig. 1A). Quantitative PCR
(Q-PCR) detection of DNase I-resistant (i.e., encapsidated)
HSV-1 DNA in the infected-cell culture supernatants demon-
strated a comparable decrease in signal, supporting the notion
that tetherin suppresses virion release from infected cells (Fig. 1B).
Tetherin expression did not affect titers of cell-associated virus
(Fig. 1C) or levels of cell-associated viral DNA (Fig. 1D) at early
time points up to 24 hpi. At later times postinfection, titers of
cell-associated virus from tetherin-expressing cells were 7- to
8-fold lower than those of controls (Fig. 1C), and consistent with
this, levels of viral proteins detected byWestern blotting were also
reduced (Fig. 1E).We assume that at these later time points, we see
the cumulative effect of tetherin’s inhibition of viral release and
the consequent reduction in number of newly infected cells in
subsequent rounds of infection. Importantly, in a plaque assay
there was no difference between tetherin-expressing and control
HT1080 cells in the number, or size, of plaques obtained from a
given virus dose, suggesting that tetherin had no impact onHSV-1
entry, or direct cell-to-cell spread (Fig. 1F). This is consistent with
the specificity of tetherin for virus release over cell-to-cell spread,
as has been described for tetherin restriction of the lentiviruses
HIV-1 and feline immunodeficiency virus (FIV) (29, 30).
We next tested whether tetherin expression could suppress
high-multiplicity infection. Tetherin-expressing and control
HT1080 cells were infected with HSV-1 (input multiplicity, 3
PFU/cell), and the virus yield was measured at various times by
plaque assay as before (Fig. 1G). Again, slightly less infectious
virus was released into the supernatant from tetherin-expressing
cells at the earliest time of 14 h, although this difference was sta-
tistically insignificant. Moreover, infectious titers in the superna-
tants were equal by 24 h after infection and up to 48 hpi. Q-PCR
detection of DNase-protected viral genomes confirmed this effect
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(Fig. 1H). Cell-associated virus titers at 14 hpi were very similar,
and infected cell lysates showed similar levels of viral proteins,
confirming that tetherin has no effect on viral DNA or protein
synthesis (Fig. 1I and J). These data suggest that during high-
multiplicity infection, tetherin is antagonized byHSV-1 infection.
To test whether tetherin protein levels were impacted by HSV-1
infection, we measured them by immunoblotting at various time
points after HSV-1 infection at an input multiplicity of 2 PFU/cell
(Fig. 1K). We found that tetherin levels declined as viral protein
FIG 1 Human tetherin restricts HSV-1 particle release. HT1080 cells express-
ing HA-tagged tetherin (THN) or empty vector (Vector) were infected with
HSV-1 SC16 at 0.01 (A to E) or 3 PFU/cell (G to J). Supernatants were har-
vested at the indicated times and titrated for HSV-1 infectivity by plaque assay
(A and G) or subjected to DNase I treatment followed by Q-PCR for the gB
gene UL27 (B and H). At the same time, cells were harvested, and freeze/
thawed 3 times before titration for HSV-1 infectivity on Vero cells (C and I),
extracted DNA was subjected to Q-PCR for the gB gene UL27 (D), or lysates
were analyzed by immunoblotting (E and J). Statistical significance, as a P
value, was determined by 2-way analysis of variance (ANOVA) (**, P 0.01;
***, P 0.001). Tetherin had no effect on DNA replication up to 22 hpi (D)
(2-way ANOVA; P 	 0.05). After high-MOI infection (3 PFU/cell), tetherin
had no effect on HSV-1 supernatant titers (G) (2-way ANOVA; P	 0.05), or
cell-associated virus titers (I) (t test; P 	 0.05). (F) HT1080 cells expressing
HA-tagged tetherin or empty vector were infected with HSV-1 SC16 and
washedwith acid citrate buffer 1 h later, before the addition of overlaymedium
for plaque assays. Plaqueswere counted 48 h later after crystal violet staining or
immune-alkaline phosphatase staining (for the plaques shown). Results are
means and standard errors of the means (SEM) and are from 3 independent
experiments. (K, L) HT1080 cells expressing HA-tagged tetherin or empty
vector were infected with HSV-1 SC16 (2 PFU/cell), and cell lysates were pre-
pared at the indicated times and analyzed by immunoblotting to detect VP5
expression and HA tag (tetherin), transferrin receptor (TfR), -actin, and
GAPDH after membrane stripping (K), or tetherin and GAPDHmRNA levels
were assessed in noninfected and infected cells by Q-PCR. Under these condi-
tions, tetherin mRNA was not detectable in the empty vector HT1080 cells.
HSV-1 infection decreased tetherinmRNA copy number (L) (2-way ANOVA;
P 0.01). Results are means and standard deviations (SD) and are represen-
tative of at least 2 separate experiments, except when specified.
FIG 2 shRNA-mediated depletion of tetherin increases HSV-1 release. HeLa
cells were transduced with HIV-1 vector encoding either of 2 tetherin-specific
shRNAs or a shRNA targeting GFP (A to C). Cells were then infected with
HSV-1 SC16 (0.1 PFU/cell). HSV-1 infectivity in the supernatants was mea-
sured by plaque assay (A) and that in DNase-protected genomes by Q-PCR
(B). Tetherin mRNA depletion was assessed in HeLa by Q-PCR normalized to
GAPDH (C). The increase in HSV-1 titers after tetherin depletion (A) was
significant (2-way ANOVA; P 0.05). Tetherin reductionwas also assessed by
immunoblotting HA tag (tetherin) or -actin (after membrane stripping) in
shRNA-transduced HA-tagged-tetherin-expressing HT1080 cells (D). Results
are means and SD and are representative of 3 separate experiments.
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VP5 increased. We assume that the different tetherin bands ob-
served represent differently glycosylated forms (31). Importantly,
all were reduced after infection. The loss of tetherin expression
was somewhat specific, as-actin and transferrin receptor protein
levels were unaffected up to 16 h after infection andGAPDH levels
were only slightly reduced (Fig. 1K). We next measured tetherin
and GAPDH mRNA levels by quantitative RT-PCR in the same
samples as Fig. 1K. We found that tetherin mRNA levels declined
with a time course similar to that of protein levels, suggesting a
role for the virus host shutoff (Vhs) function in which host
mRNAs are degraded by the Vhs protein, encoded by the HSV-1
UL41 gene (Fig. 1L). GAPDHmRNA was also lost, although with
less concomitant reduction in protein expression. We conclude
that tetherin is partly antagonized through suppression of expres-
sion and that this likely accounts for the loss of restriction after
high-multiplicity infection (Fig. 1G). These data are consistent
with the recently reported antagonism of tetherin by the HSV-1
Vhs response (see the accompanying paper [32]) but do not rule
out the possibility that tetherin might be degraded through addi-
tional mechanisms.
Tetherin depletion with shRNA increases HSV-1 release. To
confirm that tetherin was responsible for the reduction in HSV-1
release seen in Fig. 1A, we depleted endogenous tetherin expres-
sion from HeLa cells and measured release of HSV-1 into the
supernatant at various times after low-multiplicity infection (0.1
PFU/cell). HeLa cells are known to express amounts of tetherin
that restrict HIV-1 strains lacking the tetherin antagonist Vpu
(27). We used two tetherin-specific shRNAs and a control shRNA
targeting GFP. Expression of either of the anti-tetherin shRNAs
improved the release of virus, as indicated by an increase in infec-
tious titer in supernatants particularly after 39 hpi, comparedwith
the titer obtained from cells expressing shGFP (Fig. 2A). Q-PCR
detection of DNase-protected genomes confirmed that less virus
was released from cells expressing the GFP-specific shRNA (Fig.
2B). Quantitative RT-PCR showed that endogenous tetherin
mRNA levels were reduced in HeLa cells expressing tetherin-spe-
cific shRNA compared to cells expressing the hairpin targeting
GFP (Fig. 2C). The effect of shRNA expressionwas also confirmed
by immunoblotting detecting the HA tag in extracts of HT1080
cells expressingHA-tagged tetherin (Fig. 2D) and transducedwith
shRNA-encoding lentivectors.
Tetherin induces accumulation ofHSV-1 particles at the cell
surface. Having established that tetherin can restrict HSV-1 re-
lease, we sought to visualize restricted virus on the surfaces of
tetherin-expressing cells. Thin-section electron microscopy re-
vealed that in HSV-1-infected HT1080 cells that do not express
tetherin, there were few virions associated with the cell surface.
However, in infected cells overexpressing tetherin, there were ar-
eas of cell surface where many virions were associated with the
plasma membrane (Fig. 3A to G). To quantify this effect, we
counted cell surface-associated virions on control and tetherin-
expressing cell profiles in a blinded manner. In two experiments,
tetherin-expressing cells had significantlymore cell surface virions
per cell profile than control cells (Table 1; Fig. 3H). These obser-
vations are consistent with tetherin suppressing HSV-1 release
from infected cells (Fig. 1).
HSV-1 glycoprotein M can antagonize tetherin. Viruses typ-
ically encode countermeasures to the repertoire of restriction fac-
tors expressed by their natural host. Numerous viral countermea-
sures to tetherin have been described (2, 4–8, 10, 11) which share
one key mechanistic characteristic: they remove tetherin from the
location of its antiviral activity. Importantly, glycoproteins from
unrelated viruses, including lentiviruses (HIV-2 and SIVtan) (26,
29) and Ebola virus (33), have been shown to have anti-tetherin
activity. With this in mind, we hypothesized that the HSV-1 en-
velope glycoprotein M (gM) may also act as a tetherin antagonist.
This protein has been shown to relocalizemembrane proteins (23,
34), and a deletionmutant replicates to reduced titers in a number
of cell lines (23, 28, 35).
To investigate whether gM has a role in tetherin antagonism,
we first used confocal immunofluorescence microscopy to inves-
tigate the effect of gM expression on tetherin localization. We
cotransfected HEK293T cells with plasmids encoding HSV-1 gM
andHA-tagged tetherin and examined their localization after 48 h
(Fig. 4A). In cells that did not express gM, or expressed low levels
of gM (Fig. 4A, open arrowheads), tetherin was predominantly
localized to the plasma membrane, as described previously (2).
However, in cells staining brightly for gM, a significant proportion
of the tetherin was localized in the perinuclear region of the cell,
where it overlapped with gM labeling (solid arrowheads). Further
investigation indicated that the gM labeling also overlapped with
labeling for the trans-Golgi network marker TGN46 (Fig. 4B),
suggesting that tetherin-gM complexes are located in the TGN.
Together, these data suggest that, like HIV-1 Vpu, gM can relocal-
ize tetherin, consistent with its having a role in antagonizing the
restriction of virus release.
In order to assess the specificity of tetherin antagonism by gM,
we compared the localization of tetherin after expression of gM
and HSV-1 glycoproteins gD and gB. As before, we expressed the
glycoproteins transiently, together with HA-tagged tetherin, in
HEK293T cells and stained tetherin and each glycoprotein using
specific antibodies.We found that, as before, gM caused a relocal-
ization of tetherin from the plasmamembrane to an internal com-
partment (Fig. 5A). On the other hand, gD had no such effect, and
tetherin mostly localized to the cell surface, as in control cells. On
expression of gB, we found that there was a less extensive relocal-
ization of tetherin than after gM expression.We conclude that gD
has no tetherin relocalization activity and that gB may have some
activity but less than that of gM.
To examine tetherin antagonism by HSV-1 glycoproteins fur-
ther, we used flow cytometry to quantify tetherin surface expres-
sion when tetherin was coexpressed with glycoproteins, again in
HEK293T cells. Consistent with the immunofluorescence data,
fluorescence-activated cell sorting analysis showed reduced levels
of tetherin on the surfaces of gM-expressing cells compared to
cells expressing empty vector (Fig. 5B). We used the HIV-1 teth-
erin antagonist Vpu as a positive control in these experiments. gD
expression had no effect, whereas gB caused a small reduction of
tetherin surface staining that was less than that caused by gM (Fig.
5B). All glycoproteins were expressed efficiently, as measured by
immunoblotting (Fig. 5C), and there was a striking elevation in
the amount of tetherin in the gM-expressing cells, consistent with
the gM-driven accumulation in the TGN (Fig. 4B). The flow cy-
tometry measurements (Fig. 5B) were therefore consistent with
immunofluorescence staining of tetherin expression (Fig. 5A).
For a functional assessment of the antagonistic effect of HSV-1
glycoproteins on tetherin and to provide further mechanistic in-
sight, we asked whether they could substitute for Vpu in anHIV-1
release assay (27). HIV-1 particles released into the supernatant
were detected by immunoblotting for the HIV-1 Gag structural
Restriction of HSV-1 by Tetherin
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protein p24 at 48 h posttransfection. As expected, Vpu expression
effectively antagonized tetherin restriction, and HIV-1 particles
(p24-CA) were detected in the culture supernatant at levels equiv-
alent to those obtained in the absence of tetherin (Fig. 5D). When
we replaced Vpu with gM, we saw a comparable rescue of HIV-1
release (intracellular-p55/supernatant-p24 ratios are shown in
Fig. 5D). These data demonstrate that gM can rescue HIV-1 re-
lease from tetherin restriction and are consistentwith gMacting as
an antagonist of the antiviral function of tetherin during HSV-1
infection. Importantly, neither gB nor gD was able to rescue
HIV-1 release. Thus, while gB had a weak effect on tetherin local-
ization, it was unable to functionally substitute for Vpu in an assay
directly measuring functional antagonism of tetherin. These ob-
servations suggest that gMhas specificity in antagonizing tetherin.
Clearly, this model system depends on overexpression of Vpu and
gM, likely in excess of the levels achieved during an infection;
nevertheless, it allows a useful functional comparison between
unrelated molecules and provides an independent demonstration
that gM has anti-tetherin activity.
We next asked whether the tetherin antagonism shown by gM
facilitated release of HSV-1 from infected cells. We infected con-
trol and tetherin-expressing HT1080 cells with HSV-1 SC16
(WT), a gM deletion virus (gM), or a revertant virus (RgM)
using a low input multiplicity (0.01 PFU/cell). Titers of the three
viruses released from control cells were indistinguishable (Fig.
6A). However, on cells overexpressing tetherin, while all three
viruses were inhibited, thegM virus was inhibited by a small but
statistically significant degree over 48 h (2- to 3-fold) (Fig. 6B).We
reasoned that, as in the experiments whose results are shown in
Fig. 1, tetherin overexpression largely saturated HSV-1 tetherin
antagonism, leading to inhibition of all three viruses. Slightly
stronger restriction of the gM virus was likely due to its reduced
ability to antagonize tetherin. Importantly, there was no signifi-
FIG 3 Tetherin retains HSV-1 particles at the cell surface. HT1080 cells expressing HA-tagged tetherin (A to E) or empty vector (F and G) and infected with
HSV-1K26GFPwere examined by electronmicroscopy. The boxed areas inA, B, C, and F are shown at highermagnification in panels C,D, E, andG, as indicated.
N, nucleus. The asterisks mark accumulations of viral nucleocapsids. The bracket marks a layer of viruses at the cell-cell interface in panel B. In panels D, E, and
G, selected HSV-1 particles with typical morphology are indicated by the black arrows, while some of the more tangentially cut electron-dense viral profiles are
marked with black arrowheads. Bars, 10m (A, B, and E) and 1m (C, D, E, and G). (H) Counts of cell surface virus particles from both experiments (Exp) are
plotted. Open symbols, particle counts from cells expressing vector; filled symbols, counts from HA-tetherin expressing cells. The number of cells analyzed is
indicated at the bottom. Values are means
 standard deviations; P values were determined using an unpaired t test with Welch’s correction on cells having at
least one viral particle on the cell surface. (Panels A to G show data from experiment 1.)
TABLE 1 HSV-1 particle counting at the cell surface
Expt and
cellsa
No. of:
Cell profiles
examined
Infected
cellsb
HSV-1 profiles
at the cell
surface
Cell surface HSV-1
particles per
infected-cell
profile
1
Vector 60 32 419 13.09
THN 51 33 1,258 38.12
2
Vector 62 20 389 19.45
THN 70 27 886 32.81
a THN, HT1080 cells expressing HA-tagged tetherin; Vector, HT1080 cells expressing
empty vector.
b Cell profiles showing at least one viral particle at the cell surface.
FIG 4 gM relocalizes tetherin to a TGN46-positive compartment. HEK293T
cells expressing HA-tetherin alone or with HSV-1 gM were stained with an-
ti-HA (red), anti-gM (A) or TGN46 (B) (green), and DAPI (blue; nuclei). (A)
The last panel is an enlargement of the area marked on the Overlay  DAPI
panel. Open arrowheads indicate tetherin predominantly localized to the
plasmamembrane in cells not expressing or expressing low levels of gM. Solid
arrowheads (in cells staining brightly for gM) indicate tetherin localized to
perinuclear regions and colocalized with gM. Images are representative of at
least 2 separate experiments. Bars, 20 m.
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cant difference between the HT1080 lines in the number of
plaques obtained for any of the viruses for a given dose (Fig. 6C).
Absence of gM fromgM-infected cells was confirmed by immu-
noblotting for gM protein in infected-cell extracts (Fig. 6D). Fi-
nally, we infected HT1080 overexpressing HA-tagged tetherin
with RgM or gM viruses and analyzed cell lysates by Western
blotting, detectingHA-tetherin, theHSV-1 capsid proteinVP5, or
-actin as a loading control, at various time points postinfection
(Fig. 6E). As early as 4 to 6 hpi, we observed a reduction of tetherin
protein in infected cells compared to noninfected cells, as previ-
ously shown (Fig. 1K). Tetherin was almost completely lost by 10
hpi. gM expression was not responsible for loss of tetherin, as
indicated by the observation that the gM virus infection also led
to tetherin loss. These data indicate that while HSV-1 gM can act
as a tetherin antagonist, the virus has at least one other anti-teth-
erin activity responsible for loss of tetherin protein.
DISCUSSION
Here we extend the repertoire of tetherin-restricted viruses to
HSV-1 and the list of tetherin antagonists to include the HSV-1
glycoprotein gM. It is striking that glycoproteins are common as
tetherin antagonists, with anti-tetherin activity being described
for glycoproteins from the lentiviruses SIVtan and HIV-2 as well
as the filovirus Ebola virus (4, 6, 10). Our data suggest a complex
relationship between tetherin and HSV-1. Tetherin is clearly an-
tagonized by HSV-1 in at least two independent ways, by gM-
mediated relocalization and through a gM-independent suppres-
sion of tetherin mRNA (Fig. 1), likely through the Vhs response
(32).
The modest effect of tetherin on HSV-1 replication in our ex-
periments may be because HSV-1 is largely insensitive to tetherin
restriction. However, we speculate that gM’s role as a tetherin
antagonistmay not solely be to improveHSV-1 release. Rather, its
presence within incoming virions might be important for sup-
pressing tetherin innate signaling. Tetherin activates innate im-
mune signaling cascades via NF-B, inducing an innate immune
response on engagement with virus (36). As a pattern recognition
receptor, tetherin may be a particularly important target for early
antagonism before Vhs takes effect. The ability of gM to rescue
HIV-1 from tetherin restriction provides good evidence for func-
tional tetherin antagonism by gM. Rescue of HIV-1 from tetherin
restriction by gM appears to bemore potent than rescue of HSV-1
from tetherin (compare Fig. 5, HIV-1, with Fig. 6, HSV-1). We
assume that this is in part because, in the case ofHIV-1, all tetherin
antagonism is abrogated by deletion of Vpu, and thus tetherin
restriction is maximal and entirely rescued by gM expression.
However, in the case of HSV-1, in the absence of gM, tetherin is
still antagonized byVhs (32) and potentially other, as-yet-unchar-
acterized viral functions. Indeed, gB had aminor effect on tetherin
localization measured by immunofluorescence staining and flow
cytometry, although it had no effect in an HIV-1 tethering assay.
gD had no measurable effect in any of our assays.
How gM achieves ligand specificity remains unknown, but we
note thatHIV-1Vpu is also promiscuous, removingmultiple pro-
teins from the cell surface (37–40). It is unclear whether gM ac-
FIG 5 Ability of HSV-1 glycoproteins to remove tetherin from the cell surface and rescue HIV-1 from restriction. HEK293T cells expressing HA-tetherin alone
or with HSV-1 gM, gD, or gB were stained with anti-HA (red) and anti-gM, anti-gD, or anti-gB (green), respectively, and DAPI (blue; nuclei). Images are
representative of 2 separate experiments. Bars, 20 m. (B) Flow-cytometric detection of cell surface tetherin on HEK293T cells expressing HA-tetherin alone
(EV) or in combination with 3 different amounts (250, 500, and 1,000 ng) of gM, gD, or gB plasmids. Cells transfected with 1,000 ng of a Vpu plasmid were used
as a control.Mean fluorescence intensities for tetherin are plotted as a percentage of the EV value. Data shown aremeans of 3 or 4 experiments
 SEM. Statistical
significance was determined using a t test comparing mean fluorescence intensity from cells transfected with 1,000 ng of plasmids (*, P 0.05; ***, P 0.001;
NS, not significant). (C) Cells transfected for the flow-cytometric assay (B) were used for immunoblotting gM, gD, gB, HA-tetherin, and-actin, sequentially on
the same membrane after stripping. (D) HEK293T cells were cotransfected with 3 HIV-1 vector plasmids and, in addition, an empty (no THN) or tetherin
expression (EV) vector, or a tetherin expression vector plus 3 different amounts (as in panels B and C) of gM, gD, gB, or Vpu plasmids. p24 capsid (CA) in
supernatants (virions) and p55 Gag expression in cell lysates, as well as glycoprotein expression, were analyzed 48 h later by immunoblotting, with -actin used
as a loading control after membrane stripping. Intracellular-p55/supernatant-p24 ratios are indicated below the p24-stained membranes and are relative to the
ratio obtained with no tetherin. “ND” indicates that ratios could not be determined due to the absence of any p24 band. The image is representative of at least 3
experiments.
FIG 6 gM antagonizes tetherin during HSV-1 infection. Control (A) and
HA-tagged-tetherin-expressing (B) HT1080 cells were infected with HSV-1
SC16 (WT), a gM deletion virus (gM), or a revertant virus (RgM) at 0.01
PFU/cell, and supernatants harvested at the indicated times postinfectionwere
titrated for HSV-1 infectivity by plaque assay. Two-way ANOVA of 3 separate
tetherin expression experiments confirmed statistically significant differences
attributable to time and the presence of gM (P 0.01). (C) HSV-1 SC16WT,
gM, and RgM were plaque assayed on cell lines used for panels A and B.
Results are means and SEM and are from 2 independent experiments. (D)
Immunoblot detection of ICP4, gM, and -actin in lysates of HT1080 cells
infected with the 3 viruses or noninfected (NI). (E) Immunoblot detection of
VP5 and HA tag (tetherin), or -actin after membrane stripping, in lysates of
HA-tagged tetherin-expressing HT1080 cells infected with gM () or RgM
(R) virus at 2 PFU/cell or noninfected (). Results are representative of 3
separate experiments.
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tively removes tetherin or whether, like HIV-1 Vpu, gM prevents
tetherin from reaching the cell surface (41, 42). Regardless, the
result is accumulation of tetherin, detected by immunoblotting
(Fig. 5C) and the presence of tetherin in a compartment positive
for TGN46 staining (Fig. 4B). Notably, HIV-2 Env also relocalizes
tetherin to a TGN46 positive compartment without degrading it
(6). Thus, it appears that, in common with other viral tetherin
countermeasures, gM acts by removing tetherin from the site of
virus budding, in this case TGN46-negative endocytic tubules
(33). We envisage the interaction between tetherin and outgoing
HSV-1 virions occurring in this compartment, and the relocaliza-
tion of tetherin we observed by immunofluorescence (Fig. 4B)
provides a plausible basis for the anti-tetherin activity of gM. We
did not see any chains of tethered virions similar to those formed
by tetherin-restricted lentiviruses (2). Thismay reflect spatial con-
straints imposed by budding into tubules. Indeed, we assume that
newly budded tethered virions would not be readily apparent by
electron microscopy because they would simply be restrained at
the location in which they normally reside. However, following
release, virions would remain tethered to the cell surface, as we
observed (Fig. 3). This phenomenon may provide some explana-
tion as to how tetherin restricts release of HSV-1 and not direct
cell-to-cell spread, reflected by the lack of impact on plaque size.
We assume that surface-tethered virions may be able to interact
with target cell receptors to initiate infection despite being teth-
ered to the infected cell membrane. Such a process has been de-
scribed for the lentiviruses HIV-1 and FIV (29, 30).
Redundant herpesvirus-encoded tetherin antagonists are also
found inKSHV (15, 16, 43). KSHVencodes the E3 ubiquitin ligase
K5, which recruits tetherin to cause its degradation yet can still
antagonize tetherin after K5 depletion with RNA interference
(16). Thus, large viruses, such as herpesviruses, may encode sev-
eral partially redundant tetherin antagonists that have subtly dif-
ferent roles in restriction factor antagonism. The complex rela-
tionship between herpesviruses and tetherin may also explain the
puzzling result that while HSV-1 and KSHV are restricted by teth-
erin, this protein has been reported to act as a cofactor for HCMV
replication (15–17). Tetherin expression improves HCMV infec-
tivity a few-fold, perhaps related to its ability to stabilize lipid rafts,
which play a key role inHCMV entry (44, 45).We did not observe
an equivalent enhancement with HSV-1 (Fig. 1 and 2), and it
remains unclear whether HCMV also encodes proteins that ma-
nipulate tetherin to prevent it from restricting the virus.
The increasing variety of viruses that are restricted by tetherin
illustrates the power of a restriction factor that targets the funda-
mental processes of viral budding and release. The diversity of
tetherin antagonists that viruses have evolved also emphasizes the
importance of overcoming this system of host defense. It is likely
that the study of the ongoing evolutionary conflict between vi-
ruses and tetherin, which is suggested by the Red Queen hypoth-
esis (46), will lead to significant enhancements to our understand-
ing of the cell biology of both viruses and their hosts and the
relationships between them.
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